Quick Answer
Protara Therapeutics, Inc. reported Diluted EPS of $1.34 per share (loss) for fiscal year 2025.
Protara Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.34 | +38.2% |
| 2024 | -$2.17 | +39.2% |
| 2023 | -$3.57 | +39.1% |
| 2022 | -$5.86 | -39.2% |
| 2021 | -$4.21 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.31 | +38.0% | +11.4% |
| June 30, 2025 | -$0.35 | +22.2% | -20.7% |
| March 31, 2025 | -$0.29 | +70.1% | +42.0% |
| September 30, 2024 | -$0.50 | +42.5% | -11.1% |
| June 30, 2024 | -$0.45 | +55.0% | +53.6% |
| March 31, 2024 | -$0.97 | -21.2% | -11.5% |
| September 30, 2023 | -$0.87 | -27.9% | +13.0% |
| June 30, 2023 | -$1.00 | -31.6% | -25.0% |
- Protara Therapeutics, Inc. showed an increase of +38.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Protara Therapeutics, Inc.’s diluted eps has grown by 68.2% (from $4.21 per share (loss) to $1.34 per share (loss)).
- The most recent figure is from Protara Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: